Draft:Allurion Technologies

Allurion Technologies is a global medical device company focused on weight loss. The company researches, develops and markets medical and digital tools to help people lose weight.

The company makes The Allurion Gastric Balloon, is a Non-Endoscopic Intragastric Balloon. The Allurion Gastric Balloon, except under exceptional circumstances, does not require endoscopy or surgery for placement or removal.

Allurion went public in August 2023 and trades on the NYSE.

The Allurion Gastric Balloon System
Procedureless, or non-endoscopic, intragastric balloons offer a promising alternative to historic endoscopic balloons. Non-endoscopic balloons are also a less invasive alternative to weight-loss surgery.

In 2015, Allurion's gastric balloon became the world's first non-endoscopic swallowable gastric balloon when it gained approval in Europe. Except under exceptional circumstances, it does not require endoscopy or surgery for placement or removal. The non-endoscopic gastric balloon capsule is swallowed for placement and once in the stomach is filled with saline liquid. After approximately 4 months, the non-endoscopic gastric balloon then self-deflates and passes naturally at the end of placement. A recent meta analysis of 6 studies found the balloon was a safe device offering effective weight loss. Total pooled weight loss at the completion of treatment (4–6 months) was 12.8% and at 12 months was 10.9%.